MADRIGAL PHARMACEUTICALS, INC. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Madrigal executed a Third Amendment to its Financing Agreement with LSI Financing LLC (dated May 4, 2026) modifying the definition of Permitted Acquisition; specific dollar/percentage changes are redacted. Separately, Madrigal engaged Dr. Rebecca Taub as an independent consultant effective July 1, 2026 through July 1, 2027 (renewable). Compensation amount and detailed services (in Exhibit A) are not disclosed in the filing excerpt. The amendment was conditioned on effectiveness of a License Agreement with Arrowhead Pharmaceuticals.
Why this rating
Routine debt facility amendment and standard consulting engagement. No disclosed financial impact; redactions prevent quantification. No material change to financial position or strategy evident.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.